The Reaction About Anti-Hypertensive Drugs According to Plasma Renin-Aldosterone States

Year : 2025 | Volume : 15 | Issue : 02 | Page : 14 23
    By

    Il Gwang Choe,

  1. Student, Pyongyang general hospital (Pyongyang, DPRK), Okryu dong No1 Daedonggang district PyongYang city, DPRK, North Korea

Abstract

With recent studies, hypertension has not only a simple pathophysiology, thus it can classify details more about and establishing drug therapy strategies compatible with it is a very important method to improve the organ predictive of patients. The purpose of this study is to compare the responsibility of some anti-hypertensive drugs in hypertensive patients according to plasma renin-aldosterone levels, which becomes the background factor of hypertension. We investigated 71 hypertensive men. We included patients whose official hypertensive is 150/100 mmHg over, but we excluded patients with secondary hypertensions with target organ disorders, with unclear blood pressure measurement because of arrhythmia. We applied DRC (direct renin concentration), PAC (plasma aldosterone concentration) tests for 14 days in all the members. The tests are performed with blood samples that can be obtained at the rest site using with JL12316 measurement instrument. We administrated 5 drug therapy (hypothiazide 25 mg/d, Losartan 50 mg/d, amlodipine 5 mg/d, hypothiazide and Losartan12.5/50 mg, amlodipine and Losartan 5/50 mg) to the hypertensive patients. We set 14 days as the drug therapy duration until drug effect estimation, and administered all drugs between 6 and 8 A.M. After drug therapy, we compared with responsibility of anti-hypertensive drugs according to plasma renin and aldosterone levels. The response to anti-hypertensive drugs in hypertension patients is regulated by plasma aldosterone concentration, and the PAC is higher, the responsibility of anti-hypertensive drugs is lowered.

Keywords: Plasma renin activity (PRA), plasma aldosterone level, low renin hypertension, autonomic aldosterone release, anti-hypertensive therapy.

[This article belongs to Research and Reviews: A Journal of Pharmacology ]

How to cite this article:
Il Gwang Choe. The Reaction About Anti-Hypertensive Drugs According to Plasma Renin-Aldosterone States. Research and Reviews: A Journal of Pharmacology. 2025; 15(02):14-23.
How to cite this URL:
Il Gwang Choe. The Reaction About Anti-Hypertensive Drugs According to Plasma Renin-Aldosterone States. Research and Reviews: A Journal of Pharmacology. 2025; 15(02):14-23. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=208648


References

1. Abe K, Irokawa N, Aoyagi H, Seino M, Yasujima M. Low renin hypertension–is it a stage of essential hypertension? Tohoku J Exp Med. 1977 Apr;121(4):347-54. doi: 10.1620/tjem.121.347.
2. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP, Piaditis G. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011 Nov;41(11):1227-36. doi: 10.1111/j.1365-2362.2011.02531.x.

3. Giacchetti G, Mulatero P, Mantero F, Veglio F, Boscaro M, Fallo F. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends Endocrinol Metab. 2008 Apr;19(3):104-8. doi: 10.1016/j.tem.2008.01.005.
4. Nanba K, Vaidya A, Rainey WE. Aging and Adrenal Aldosterone Production. Hypertension. 2018 Feb;71(2):218-223. doi: 10.1161/HYPERTENSIONAHA.117.10391.
5. Honda M, Izumi Y, Tsuchiya M, Ueda Y, Watanabe H, Inoue T, Shiratsuchi T, Hatano M. A simplified screening test for differentiating primary aldosteronism from essential hypertension with low plasma renin activity. Jpn Circ J. 1980 Sep;44(9):719-25. doi: 10.1253/jcj.44.719
6. Mukhin.N.A. Renin as a target of direct pharmacological block in arterial hypertension.Ter Arkh. 2009:81(8):5-9.
7. Paolo Mulatero ,Andrea Verhovez, Fulvio Morello ,Franco Veglio .Diagnosis and treatment of low-renin hypertension. Clinical Endocrinology 2007;67.324-334.
8. Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, Vaidya A. Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension. 2017 May;69(5):950-956. doi: 10.1161/HYPERTENSIONAHA.116.08952.
9. Dluhy RG, Williams GH. Aldosterone–villain or bystander? N Engl J Med. 2004 Jul 1;351(1):8-10. doi: 10.1056/NEJMp048132.
10. Tolagen K. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects. Scand J Clin Lab Invest. 1978 Sep;38(5):487-93. doi: 10.1080/00365517809108455.
11. Tolagen K, Karlberg BE. Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects. Scand J Clin Lab Invest. 1978 May;38(3):241-7. doi: 10.3109/00365517809108418.
12. Liu Z, Jin L, Zhou W, Zhang C. The spectrum of plasma renin activity and hypertension diseases: Utility, outlook, and suggestions. J Clin Lab Anal. 2022 Nov;36(11):e24738. doi: 10.1002/jcla.24738.

Regular Issue Subscription Original Research
Volume 15
Issue 02
Received 25/02/2025
Accepted 08/03/2025
Published 24/04/2025
Publication Time 58 Days
263

Login


My IP

PlumX Metrics